Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | Treatment methods in mantle cell lymphoma

Stephen Robinson • 26 Mar 2017
EBMT 2017
Mantle Cell Lymphoma

Dr. Stephen Robinson of the Bristol Hematology Oncology Centre discusses the treatment methods involved in mantle cell lymphoma (MCL). MCL is a type of non-Hodgkin lymphoma with a relatively poor prognosis. The first-line treatment in response to MCL is an autologous transplant, other treatments include allogeneic transplantation however, there is no definitive treatment plan. A large retrospective study with EBMT was carried out to investigate the efficacy of allogeneic transplantation in MCL and results suggest that it should not be used as a first-line treatment due to evidence of association with significant toxicity. Recorded at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation

More from Stephen Robinson

CAR T-cells in hematological malignancies 1:15
CAR T-cells in hematological malignancies
Stephen Robinson • 14 Apr 2018
Hodgkin lymphoma: when autologous transplant is unsuccessful 1:11
Hodgkin lymphoma: when autologous transplant is unsuccessful
Stephen Robinson • 14 Apr 2018
The future of CAR T-cell therapy 2:30
The future of CAR T-cell therapy
Stephen Robinson • 14 Apr 2018
Autologous stem cell transplantations: BEAM or BEAC? 2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson • 26 Mar 2017

Related Videos

The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more 15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Michael Wang et al. • 27 Sep 2025
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials 14:48
An update on BTK-targeting therapies in NHL & CLL: combinations, BTK degraders, and ongoing trials
Alexey Danilov et al. • 28 Sep 2025
The content of VJHemOnc is intended for healthcare professionals